Eyeworld Daily News

EW SHOW DAILY 20 ASCRS News Today Saturday, May 6, 2017 play a role in "making myopia great again." The myopic population, said Michael Lachman, president, EyeQ, San Francisco, is heavily weighted toward the low end of the myo- pic spectrum, which he defined as between –0.5 D to –2 D. Forty-seven million American adults fall into the low myopia category. From a refractive surgery standpoint, only also announced TearScience's Activa- tor II for the LipiFlow, which he said is meant to reduce medical waste and make the device faster to use. A panel of ophthalmologists— Alice Epitropoulos, MD, Columbus, Ohio, Sam Garg, MD, Irvine, Cal- ifornia, Terry Kim, MD, Durham, North Carolina, and Stephen Lane, MD, Minneapolis—discussed innovation in dry eye, expressing particular interest in the various diagnostic modalities, the opportu- nity that nanotechnology presents in the realm of drug delivery, how devices are playing a role in dry eye, and more. Shifting gears, a panel assem- bled to discuss opportunities for correction of low myopia that could 10–15% of patients are being treated surgically for low myopia, Mr. Lachman said. Stephen Slade, MD, Houston, facilitated a discussion of the various refractive correction options— PRK, LASIK, PiXL (photorefractive intrastromal crosslinking, Avedro, Waltham, Massachusetts), SMILE (small incision lenticule extraction, Carl Zeiss Meditec, Jena, Germany), and contact lenses—among the pan- el, which included Laurent Attias, senior vice president, Alcon, Fort Worth, Texas; Terence Koritz, vice president, global strategic market- ing, surgical, Johnson & Johnson Vision, Santa Ana, California; Rajesh Rajpal, MD, CMO, Avedro; Steve Schallhorn, MD, CMO, Carl Zeiss Meditec; and Calvin Roberts, MD, senior vice president and CMO, Bausch + Lomb, Bridgewater, New Jersey. The pros and cons of the various options were debated as to whether they could bring low myopes to the market. In the end, the audience voted via a polling app that they thought LASIK and PiXL present- ed the best opportunity to make refractive surgery more attractive to patients with low myopia. The afternoon session also included a discussion on the role of the "mega-practice" and private equity partnership in eyecare deliv- ery. OIS concluded with the Masters of Industry discussion, which was moderated by William Link, PhD, managing director, Versant Ven- tures, San Francisco. Participants included Michael Ball, CEO, Alcon; Thomas Burns, president and CEO, Glaukos, San Clemente, California; Tom Frinzi, worldwide president, surgical, Johnson & Johnson Vision; Ludwin Monz, PhD, president and CEO, Carl Zeiss Meditec; Joseph Papa, CEO, Valeant Pharmaceuti- cals, Bridgewater, New Jersey; and Perry Sternberg, head of U.S. com- mercial, Shire. EW Editors' note: The speakers at OIS have financial interests with the companies they represent. 80O.787.5426 © 2017 Haag-Streit USA. All Rights Reserved. Introducing the Fundus Module 300 slit lamp attachment. Unlike other fundus imaging systems, the Fundus Module 300 attaches to Haag-Streit slit lamps, eliminating the need for a separate, stand-alone fundus camera. Its simplicity and compatibility give you the ability to capture a retinal image in a matter of seconds, with the same accuracy and quality you require. Learn more about the Fundus Module 300. Visit HSDriven.com/fundus. Driven to excellence: The Fundus Module 300 OUR FUNDUS CAMERA ATTACHES TO OUR SLIT LAMPS. DOES YOURS? Visit us at ASCRS Booth #2013 OIS@ASCRS continued from page 18

• Cover